Inhibition of CLDN1 via monoclonal antibody was noted to be safe in nonhuman primates (62), with an active phase II clinical trial evaluating CLDN1 inhibition in patients with head and neck cancer (Clinicaltrials.gov NCT06054477). Here, CLDN1 is linked to head and neck cancer.